Publications by authors named "K Komuro"
Article Synopsis
- A 59-year-old female with multiple myeloma developed symptoms of edema and dyspnea after starting treatment with carfilzomib, a cancer drug, which raised concerns about potential drug-related cardiac complications.
- Diagnostic tests revealed signs of pre-capillary pulmonary hypertension (PH) and confirmed it through right heart catheterization, leading to the conclusion that carfilzomib was causing the condition.
- After stopping the drug and starting pulmonary vasodilator therapy, the patient experienced symptom improvement and heart changes, suggesting the need for careful monitoring for PH in patients receiving carfilzomib.
Background: In contrast to the well-known prognostic values of the cardiorenal linkage, it remains unclear whether impaired cognitive function affects cardiac prognosis in relation to cardiac sympathetic innervation and renal function in patients with heart failure (HF).
Methods And Results: A total of 433 consecutive HF patients with left ventricular ejection fraction (LVEF) <50% underwent the Mini-Mental State Examination (MMSE) and a neuropsychological test for screening of cognition impairment or subclinical dementia. Following metaiodobenzylguanidine (MIBG) scintigraphy, patient outcomes with a primary endpoint of lethal cardiac events (CEs) were evaluated for a mean period of 14.
Article Synopsis
- Individuals with diabetes have a higher risk of developing cardiovascular disease (CVD), and this study aimed to understand how modifiable risk factors relate to CVD based on diabetes status.
- The analysis involved over 4 million individuals, revealing that while obesity, hypertension, and dyslipidemia had a weaker association with CVD in those with diabetes, risky behaviors like poor diet, smoking, and inactivity had a stronger impact.
- The findings indicate that maintaining a healthy lifestyle is especially crucial for people with diabetes to reduce their risk of CVD, as lifestyle-related factors significantly increase their risk compared to those without diabetes.
Introduction: We aimed to assess the safety, pharmacokinetic profile, and antitumor activity of adavosertib monotherapy in Japanese patients with advanced solid tumors.
Materials And Methods: This was a single-center, open-label, phase I study with two consecutive cohorts (250 mg and 200 mg cohorts). Patients received adavosertib at 250 mg or 200 mg, orally once daily for 5 days on and 2 days off for Weeks 1 and 2 of a 21-day cycle.